Giulia Dodi, Paola Di Filippo, Armando Di Ludovico, Pasquale Simeone, Domenico De Bellis, Francesca D'ascanio, Sabrina Di Pillo, Francesco Chiarelli, Paola Lanuti, Marina Attanasi
Department of Pediatrics, Pediatric Allergy and Pulmonology Unit, University of Chieti-Pescara, Chieti, Italy.
Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, Chieti-Pescara, 66100 Chieti, Italy.
World Allergy Organ J. 2024 Dec 9;17(12):100998. doi: 10.1016/j.waojou.2024.100998. eCollection 2024 Dec.
Basophilic granulocytes, containing and releasing histamine after a specific allergy stimulation, are directly involved in IgE-mediated allergic reactions. CD63 is a transmembrane protein of secretory lysosomes of basophils and its upregulation is related with the release of histamine to the extracellular space during IgE-mediated allergic reactions. Basophil activation test (BAT) measures the activation of circulating basophils upon the stimulation of living blood cells with specific allergens. Such a test is particularly safe and reproducible and has recently emerged as a new promising diagnostic tool for allergic diseases. BAT can be used to diagnose food allergy and represents a promising alternative to oral food challenge tests, especially in children as it is less invasive, safer, and cheaper than the gold standard tests. As a biomarker of tolerance and reactivity, it is also useful to monitor natural resolution and clinical response to immune-modulatory treatments. Regarding drug allergies, BAT is even the only possible applicable diagnostic tool for allergy reactions to some drugs, because of the lack of alternative test, or given that those commonly used are unreliable, or equivocal. Additionally, BAT allows to screen patients with more active urticarial and identify Hymenoptera-allergic patients with negative venom-specific immunoglobulin (Ig)E. In respiratory allergic diseases, BAT can facilitate the diagnosis of local allergic rhinitis and evaluate basophil allergen sensitivity in allergic asthma. Although IgE-sensitization in allergic asthma is usually demonstrated by skin prick test and specific IgE, those tests do not predict the clinical allergy contribution to asthma pathogenesis. To date, the potential of BAT in the diagnostic work-up of allergic diseases is well established, but a better standardization of its use is needed. This narrative review summarizes the state-of-the-art BAT technology and applications in pediatric allergic diseases, focusing on immune-related mechanisms and the BAT real clinical utility.
嗜碱性粒细胞在特定过敏刺激后含有并释放组胺,直接参与IgE介导的过敏反应。CD63是嗜碱性粒细胞分泌性溶酶体的跨膜蛋白,其上调与IgE介导的过敏反应期间组胺释放到细胞外空间有关。嗜碱性粒细胞活化试验(BAT)通过用特定过敏原刺激活血细胞来测量循环嗜碱性粒细胞的活化。这种试验特别安全且可重复,最近已成为一种有前途的过敏性疾病诊断新工具。BAT可用于诊断食物过敏,是口服食物激发试验的一种有前途的替代方法,特别是在儿童中,因为它比金标准试验侵入性更小、更安全且更便宜。作为耐受性和反应性的生物标志物,它对于监测免疫调节治疗的自然缓解和临床反应也很有用。关于药物过敏,由于缺乏替代试验,或者鉴于常用试验不可靠或不明确,BAT甚至是某些药物过敏反应唯一可能适用的诊断工具。此外,BAT可以筛查荨麻疹更活跃的患者,并识别毒液特异性免疫球蛋白(Ig)E阴性的膜翅目过敏患者。在呼吸道过敏性疾病中,BAT可以促进局部过敏性鼻炎的诊断,并评估过敏性哮喘中嗜碱性粒细胞过敏原敏感性。虽然过敏性哮喘中的IgE致敏通常通过皮肤点刺试验和特异性IgE来证明,但这些试验并不能预测临床过敏对哮喘发病机制的贡献。迄今为止,BAT在过敏性疾病诊断检查中的潜力已得到充分证实,但需要更好地规范其使用。这篇叙述性综述总结了BAT技术的最新进展及其在儿科过敏性疾病中的应用,重点关注免疫相关机制和BAT的实际临床效用。